Clinical Trial Update: Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating SYS6055 Injection in participants with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. The trial is currently not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• SYS6055 Injection (SYS6055)

Snippet

Sponsor: Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING